UY31786A1 - Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos oculares - Google Patents
Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos ocularesInfo
- Publication number
- UY31786A1 UY31786A1 UY31786A UY31786A UY31786A1 UY 31786 A1 UY31786 A1 UY 31786A1 UY 31786 A UY31786 A UY 31786A UY 31786 A UY31786 A UY 31786A UY 31786 A1 UY31786 A1 UY 31786A1
- Authority
- UY
- Uruguay
- Prior art keywords
- pai
- expression
- activity
- treatment
- inhibitors
- Prior art date
Links
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 title abstract 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 title abstract 3
- 208000030533 eye disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 abstract 1
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
El invento se refiere a una realizacion de un método para el tratamiento de glaucoma o la presion intraocular elevada en un paciente, que comprende administrarle una cantidad eficaz de una composicion que comprende un agente que inhibe la expresion del PAI-1 o la actividad del PAI-1. Una realizacion adicional del presente invento es un método de traamiento de un trastorno ocular asociado al PAI1 en un sujeto que lo necesite, que comprende administrar al paciente una cantidad eficaz de una composicion que comprende un agente que inhibe la actividad o la expresiondel PAI-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4817608P | 2008-04-26 | 2008-04-26 | |
US12/421,456 US20090202524A1 (en) | 2007-10-31 | 2009-04-09 | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31786A1 true UY31786A1 (es) | 2009-08-03 |
Family
ID=40810596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31786A UY31786A1 (es) | 2008-04-26 | 2009-04-24 | Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos oculares |
Country Status (10)
Country | Link |
---|---|
US (2) | US20090202524A1 (es) |
EP (1) | EP2296647A2 (es) |
JP (1) | JP2011518828A (es) |
KR (1) | KR20100135953A (es) |
CN (1) | CN102046168A (es) |
AR (1) | AR071393A1 (es) |
CL (1) | CL2009000986A1 (es) |
TW (1) | TW200946113A (es) |
UY (1) | UY31786A1 (es) |
WO (1) | WO2009131850A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2560167A1 (en) * | 2004-04-26 | 2005-11-10 | Alcon, Inc. | Statins for the treatment of ocular hypertension and glaucoma |
US10946076B2 (en) | 2013-02-13 | 2021-03-16 | The Research Foundation For The State University Of New York | Glaucoma treatment |
CR20190319A (es) | 2013-08-13 | 2019-08-29 | Sanofi Sa | ANTICUERPOS CONTRA EL INHIBIDOR DEL ACTIVADOR DE PLASMINÓGENO TIPO 1 (PAI-1) Y USOS DE LOS MISMOS (Divisional 2016-0117) |
EP3069732B1 (en) | 2013-11-14 | 2023-07-12 | The Doshisha | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage |
CA3008113A1 (en) | 2015-12-24 | 2017-06-29 | The Doshisha | Drug for treating or preventing disorder caused by tgf-.beta. signals, and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4214215A1 (de) * | 1992-04-30 | 1993-11-04 | Behringwerke Ag | Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen |
EP2130532A1 (en) * | 1999-01-05 | 2009-12-09 | University of Utah Research Foundation | Method for treating conditions associated with the accumulation of excess extracellular matrix |
DK1397130T3 (da) * | 2001-06-20 | 2007-11-12 | Wyeth Corp | Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1) |
MXPA04009471A (es) * | 2002-04-30 | 2005-01-25 | Alcon Inc | Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas. |
US8415364B2 (en) * | 2003-11-26 | 2013-04-09 | Duke University | Method of preventing or treating glaucoma |
CA2560167A1 (en) * | 2004-04-26 | 2005-11-10 | Alcon, Inc. | Statins for the treatment of ocular hypertension and glaucoma |
WO2006040839A1 (ja) * | 2004-10-15 | 2006-04-20 | Advanced Medicine Research Institute | 眼疾患処置用点眼剤及びキット |
US20060094753A1 (en) * | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US7803824B2 (en) * | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
AU2007238608A1 (en) * | 2006-04-14 | 2007-10-25 | Massachusetts Institute Of Technology | Identifying and modulating molecular pathways that mediate nervous system plasticity |
AU2007313684A1 (en) * | 2006-10-31 | 2008-05-08 | Alcon Research, Ltd. | PAI-1 binding modulators for the treatment of ocular disorders |
-
2009
- 2009-04-09 US US12/421,456 patent/US20090202524A1/en not_active Abandoned
- 2009-04-10 KR KR1020107026494A patent/KR20100135953A/ko not_active Application Discontinuation
- 2009-04-10 WO PCT/US2009/040149 patent/WO2009131850A2/en active Application Filing
- 2009-04-10 JP JP2011506352A patent/JP2011518828A/ja active Pending
- 2009-04-10 CN CN2009801185568A patent/CN102046168A/zh active Pending
- 2009-04-10 EP EP09735222A patent/EP2296647A2/en not_active Withdrawn
- 2009-04-21 TW TW098113153A patent/TW200946113A/zh unknown
- 2009-04-22 AR ARP090101418A patent/AR071393A1/es not_active Application Discontinuation
- 2009-04-24 UY UY31786A patent/UY31786A1/es not_active Application Discontinuation
- 2009-04-24 CL CL2009000986A patent/CL2009000986A1/es unknown
-
2011
- 2011-01-14 US US13/006,984 patent/US20110105574A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2296647A2 (en) | 2011-03-23 |
WO2009131850A3 (en) | 2010-01-07 |
CL2009000986A1 (es) | 2010-12-31 |
TW200946113A (en) | 2009-11-16 |
WO2009131850A2 (en) | 2009-10-29 |
KR20100135953A (ko) | 2010-12-27 |
US20110105574A1 (en) | 2011-05-05 |
US20090202524A1 (en) | 2009-08-13 |
JP2011518828A (ja) | 2011-06-30 |
CN102046168A (zh) | 2011-05-04 |
AR071393A1 (es) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
AR121843A2 (es) | Formulación oftálmica y método para mejorar la presbicia | |
CL2017002526A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015) | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
MX2019004468A (es) | Uso de lentes de contacto en el tratamiento de una afeccion oftalmologica. | |
NI201200179A (es) | Métodos de tratamiento contra el cáncer pancreático | |
BRPI0911923B8 (pt) | dispositivo para tratamento de um aneurisma cerebral | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
BR112012025581A2 (pt) | implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral | |
BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
BR112014010803A2 (pt) | método de tratamento | |
UY31786A1 (es) | Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos oculares | |
EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
GEP20237541B (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
CO6500125A1 (es) | Suministro de curcumina por derivacion | |
AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
BR112012006010A2 (pt) | composto de glicina | |
EP4324454A3 (en) | Cross-linking agents and associated methods | |
MX2009010988A (es) | Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica. | |
FR3029777B1 (fr) | Utilisation de l'association d'un polyether polyurethane non-ionique associatif et d'un derive de cyclohexanol comme agent rafraichissant de la peau | |
MX2022010960A (es) | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. | |
BR112022020441A2 (pt) | Composições compreendendo nanopartículas, método de fabricação e usos das mesmas | |
BR112014009761B8 (pt) | Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20200911 |